6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Withdrawal Syndrome Management
Managing withdrawal syndrome is a crucial aspect of addiction treatment, as withdrawal symptoms can be both physically and psychologically intense. The severity of withdrawal depends on the substance involved, the duration of use, and the individual's physical health. Symptoms can range from mild discomfort, such as irritability and fatigue, to severe effects like seizures, hallucinations, or even life-threatening complications. Medical detoxification is often the first step in managing withdrawal, involving a controlled environment where healthcare providers can monitor and treat symptoms as they arise. Medications, such as benzodiazepines for alcohol withdrawal or opioid agonists for opioid withdrawal, may be used to alleviate symptoms and reduce the risk of relapse. After detox, long-term treatment focuses on maintaining sobriety through therapy and support.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States